All In Biotech

Drug Trial Radar · NCT00147550

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

A Multicenter, Open-Label, Noncomparative Phase 1-2 Clinical And Pharmacokinetic Study Of Oral PD 0325901 In Patients With Advanced Cancer

Last checked: Nov 20, 2026Latest source record: Sep 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

79

Actual

Start

Feb 2004

Primary completion

May 2007

Study completion Jul 2013

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells. PD-325901 is a new drug designed to block this pathway and kill cancer cells. The purpose of this study is to study the effectiveness of PD-325901 in patients with colon cancer, breast cancer, and melanoma. PD-325901 will be given by mouth as a pill twice a day, CT scans will be done and biopsies will be taken of a tumor before and once during treatment to measure the effects of the drug. Blood samples will be taken to measure the amount of drug in the blood.

Conditions

  • Melanoma
  • Colonic Neoplasms
  • Breast Neoplasms

Interventions

  • PD-0325901Drug

    Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate, Safety.Time frame: duration of trial

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    La Jolla, California

  • Pfizer Investigational Site

    La Mesa, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    Santa Monica, California

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Detroit, Michigan

  • Pfizer Investigational Site

    Detroit, Michigan

  • Pfizer Investigational Site

    Rochester, Minnesota

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    Cleveland, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.